Oncogenex Sets IPO Terms

Oncogenex Technologies Inc., a Vancouver-based drug company focused on cancer therapeutics, has set its proposed IPO terms to 4.5 million common shares being offered at between $10 and $12 per share. It plans to trade on both the Nasdaq and TSX, with RBC Capital Markets serving as lead underwriter. Shareholders include Ventures West, BDC Venture Capital, GrowthWorks, HIG Capital and Milestone Medica Corp. www.oncogenex.ca< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />